ADAR1 Capital Management LLC lessened its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 56.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,826 shares of the company's stock after selling 57,000 shares during the quarter. ADAR1 Capital Management LLC's holdings in Denali Therapeutics were worth $914,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock worth $3,880,000 after buying an additional 497 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the last quarter. Pier Capital LLC increased its holdings in shares of Denali Therapeutics by 1.6% in the 3rd quarter. Pier Capital LLC now owns 168,082 shares of the company's stock worth $4,896,000 after purchasing an additional 2,596 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after purchasing an additional 2,731 shares during the last quarter. Institutional investors own 92.92% of the company's stock.
Denali Therapeutics Trading Up 1.6 %
Denali Therapeutics stock traded up $0.20 during midday trading on Friday, hitting $12.70. The stock had a trading volume of 1,626,428 shares, compared to its average volume of 1,078,596. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The firm's fifty day moving average is $16.53 and its two-hundred day moving average is $21.83. The company has a market capitalization of $1.84 billion, a PE ratio of -4.60 and a beta of 1.58.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.
Analysts Set New Price Targets
DNLI has been the topic of several recent analyst reports. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday. Stifel Nicolaus raised shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price target on the stock in a report on Monday, December 16th. JPMorgan Chase & Co. decreased their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Bank of America dropped their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $37.57.
View Our Latest Research Report on Denali Therapeutics
Denali Therapeutics Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Further Reading
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
